Tag: neurological diseases

Whole Genome Sequencing Market to Reach New Heights by 2030

"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C Wainwright 5^th Annual Ophthalmology Virtual Conference on August 13, 2025.

Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7^th, 2025.

Oculis Upsized Loan Facility to Access up to CHF 100 million

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”).

Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer’s Disease

TORONTO, July 28, 2025 /PRNewswire/ -- Qynapse, a technology company using AI to enhance the quantification and predictive capabilities of imaging to improve outcomes for...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST

G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform^™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).

Inside information: Orion upgrades full-year outlook for 2025

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025

ORION CORPORATION
PRESS RELEASE
4 JULY 2025 at 09.00 EEST

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsNeurological diseases

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

Transaction in Own Shares

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026